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Summary
Background A rapid, blood-based triage test that allows targeted investigation for tuberculosis at the point of care 
could shorten the time to tuberculosis treatment and reduce mortality. We aimed to test the performance of a host 
blood transcriptomic signature (RISK11) in diagnosing tuberculosis and predicting progression to active pulmonary 
disease (prognosis) in people with HIV in a community setting.
Methods In this prospective diagnostic and prognostic accuracy study, adults (aged 18–59 years) with HIV were 
recruited from five communities in South Africa. Individuals with a history of tuberculosis or household exposure to 
multidrug-resistant tuberculosis within the past 3 years, comorbid risk factors for tuberculosis, or any condition that 
would interfere with the study were excluded. RISK11 status was assessed at baseline by real-time PCR; participants 
and study staff were masked to the result. Participants underwent active surveillance for microbiologically confirmed 
tuberculosis by providing spontaneously expectorated sputum samples at baseline, if symptomatic during 15 months 
of follow-up, and at 15 months (the end of the study). The coprimary outcomes were the prevalence and cumulative 
incidence of tuberculosis disease confirmed by a positive Xpert MTB/RIF, Xpert Ultra, or Mycobacteria Growth 
Indicator Tube culture, or a combination of such, on at least two separate sputum samples collected within any 
30-day period. 
Findings Between March 22, 2017, and May 15, 2018, 963 participants were assessed for eligibility and 861 were 
enrolled. Among 820 participants with valid RISK11 results, eight (1%) had prevalent tuberculosis at baseline: seven 
(2·5%; 95% CI 1·2–5·0) of 285 RISK11-positive participants and one (0·2%; 0·0–1·1) of 535 RISK11-negative 
participants. The relative risk (RR) of prevalent tuberculosis was 13·1 times (95% CI 2·1–81·6) greater in RISK11-
positive participants than in RISK11-negative participants. RISK11 had a diagnostic area under the receiver operating 
characteristic curve (AUC) of 88·2% (95% CI 77·6–96·7), and a sensitivity of 87·5% (58·3–100·0) and specificity of 
65·8% (62·5–69·0) at a predefined score threshold (60%). Of those with RISK11 results, eight had primary endpoint 
incident tuberculosis during 15 months of follow-up. Tuberculosis incidence was 2·5 per 100 person-years (95% CI 
0·7–4·4) in the RISK11-positive group and 0·2 per 100 person-years (0·0–0·5) in the RISK11-negative group. The 
probability of primary endpoint incident tuberculosis was greater in the RISK11-positive group than in the RISK11-
negative group (cumulative incidence ratio 16·0 [95% CI 2·0–129·5]). RISK11 had a prognostic AUC of 80·0% 
(95% CI 70·6–86·9), and a sensitivity of 88·6% (43·5–98·7) and a specificity of 68·9% (65·3–72·3) for incident 
tuberculosis at the 60% threshold.
Interpretation RISK11 identified prevalent tuberculosis and predicted risk of progression to incident tuberculosis 
within 15 months in ambulant people living with HIV. RISK11’s performance approached, but did not meet, WHO’s 
target product profile benchmarks for screening and prognostic tests for tuberculosis.
Funding Bill & Melinda Gates Foundation and the South African Medical Research Council.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
There is an urgent need for earlier tuberculosis diagnosis. 
By use of novel non-sputum approaches linked to more 
effective preventive and curative drugs, tuberculosis 
transmission and mortality could be reduced.1,2 The 
current armamentarium of screening and diagnostic 
tests is insufficient to curb the tuberculosis pandemic. 
Symptom screening, the principal case-finding method 
worldwide, is a poor triage tool for tuberculosis in people 
living with HIV, with a sensitivity of 51%  and a specificity 
of 70·7% for people on antiretroviral therapy (ART) 
and a sensitivity of 89·4% and a specificity of 28·1% for 
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ART-naive individuals.3 The low specificity of symptom 
screening leads to many unnecessary and expensive 
confirmatory tests, and poor sensitivity in ART-treated 
people misses approximately half of active tuberculosis 
cases in people living with HIV. Several rapid and cheap 
non-sputum-based diagnostic tests have shown promise 
at the point of care; in a prospective study of individuals 
initiating ART with CD4 cell counts less than 350 cells 
per μL, C-reactive protein testing had 89·0% sensitivity 
and 72·1% specificity, and significantly reduced the 
number of confirmatory Xpert MTB/RIF tests.4,5 The 
Determine TB lipoarabinomannan (LAM) Ag assay had 
a sensitivity of only 31% among unselected outpatients 
with HIV in a Cochrane review.6
The only tests currently recommended by WHO 
to diagnose Mycobacterium tuberculosis infection are 
tuberculin skin testing and the interferon-γ (IFN-γ) 
release assay.7 One systematic review and meta-analysis 
showed that the incidence of progression to active 
tuberculosis in people with HIV and a positive  tuberculin 
skin test or IFN-γ release assay was greater than 11-times 
higher than in those with a negative test.8 However, the 
IFN-γ release assay is expensive, laborious, and requires 
skilled technicians in a centralised laboratory. Tuberculin 
skin testing is cheap and can be done at the point of care, 
but still requires the individual being tested to return for 
the result to be read within 48 h and has a low positive 
predictive value.9
A rapid, blood-based triage test that allows targeted 
investigation for tuberculosis at the point of care could 
shorten the time to tuberculosis treatment. Over the past 
decade, several host blood transcriptomic biomarkers 
have emerged with potential for diagnosing prevalent 
tuberculosis10 and predicting progression11 to disease. 
However, 16 of 17 host blood transcriptomic biomarker 
discovery or validation studies in people living with HIV 
Research in context
Evidence before this study
We searched MEDLINE, Scopus, and EBSCOHost databases for 
all studies published in English between database inception 
and May 31, 2020, using the search terms “diagnostic OR 
prognostic”, “blood”, “transcriptomic”, “biomarker”, 
“tuberculosis”, and “HIV”. We identified 17 studies reporting 
27 host blood transcriptomic biomarkers that differentiate 
people living with HIV and tuberculosis from people living 
with HIV, those with latent Mycobacterium tuberculosis 
infection, or those with other respiratory diseases. Ten studies 
used the same RNA microarray dataset of people living with 
HIV in Malawi and South Africa for either training or 
validation, potentially limiting generalisability. 16 of the 
17 studies used case-control or cross-sectional designs, 
eliminating diagnostic uncertainty and introducing inherent 
spectrum bias, which would potentially inflate diagnostic 
accuracy and limit real-world generalisability. Only one 
prospective diagnostic accuracy study tested performance in 
all enrolled participants, including those with 
microbiologically confirmed or clinically suspected 
tuberculosis, representative of the target population. 
There were no prospective cohort studies evaluating the 
prognostic performance of a host blood transcriptomic 
biomarker in people living with HIV, and no diagnostic 
accuracy studies in ambulant, predominantly asymptomatic 
community volunteers living with HIV. Published host blood 
transcriptomic signatures of tuberculosis are predominantly 
comprised of interferon (IFN)-stimulated genes known to be 
induced by viral infection, resulting in elevated signature 
scores in individuals with detectable HIV viral loads. 
Signatures developed in people without HIV might perform 
poorly in people with HIV. However, a prospective comparison 
of 27 transcriptomic signatures in symptomatic adults 
reported that the diagnostic accuracy for tuberculosis of the 
four best performing signatures was not affected by HIV 
infection. This finding was limited by a small sample size. 
No studies have evaluated clinical factors affecting 
transcriptomic signature scores in people with HIV.
Added value of this study
To our knowledge, this study is the first to prospectively use 
a real-time PCR host blood transcriptomic signature (RISK11) 
to diagnose prevalent tuberculosis and predict progression 
to incident tuberculosis in a real-world community cohort of 
ambulant people living with HIV. We found a 2·1% prevalence 
of previously undiagnosed, predominantly subclinical 
tuberculosis microbiologically confirmed on one or more 
sputum samples. Among people with HIV without prevalent 
tuberculosis at screening, most of whom were on antiretroviral 
therapy, the rate of progression to incident tuberculosis 
(microbiologically confirmed on one or more sputum samples) 
was 2·3 per 100 person-years. RISK11 diagnosed prevalent 
tuberculosis and predicted progression to incident tuberculosis 
with a performance approaching, but not meeting, 
the minimal WHO target product profile for tuberculosis triage 
and prognostic tests. The IFN-γ release assay was not a good 
predictor of progression to tuberculosis, which underscores its 
limited utility in tuberculosis-endemic settings.
Implications of all the available evidence
Traditional symptom screening would miss most undiagnosed 
prevalent tuberculosis in people with HIV in this community 
setting. The IFN-γ release assay would result in considerable 
overtreatment with preventive therapy. Host blood 
transcriptomic biomarkers have promise for community-based 
tuberculosis screening of people with HIV to guide targeted 
confirmatory diagnostic testing, enhanced surveillance, and 
preventive therapy. This study supports further development 
of host blood transcriptomic signatures into point-of-care 
testing devices for use in community-based screening of 
people with HIV.
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have used a cross-sectional or case-control design, and 
no studies have evaluated prospective, community-based 
screening in an unselected cohort of ambulant people 
with HIV, or evaluated performance for predicting 
progression to incident tuberculosis in people with HIV.
We previously developed and validated a highly specific 
16-gene biomarker to identify M tuberculosis-infected, 
HIV-uninfected adults with high risk of progression to 
active tuberculosis disease.12 In a patient-level pooled 
meta-analysis, this 16-gene signature was among eight 
transcriptomic signatures that achieved the minimum 
accuracy benchmark in WHO’s target product profile for 
incipient tuberculosis tests.11 This PCR-based, transcrip-
tomic, host-response blood signature was refined from a 
16-gene to an 11-gene signature named RISK11, with 
equivalent diagnostic and prognostic performance.13 At 
the time this study was conceived, RISK11 was the only 
published parsimonious quantitative RT-PCR transcrip-
tomic signature shown to predict progression to incident 
tuberculosis. Among adults without HIV recruited from 
the same communities as this study, RISK11 was able to 
detect microbiologically confirmed pulmonary tubercu-
losis at enrolment (area under the receiver operating 
charact eristic curve [AUC] 77%) and predict progression to 
incident tuberculosis within 12 months (AUC 80%).14 
However, results from a cross-sectional study suggest 
that performance of RISK11 at discriminating prevalent 
tuberculosis disease from latent M tuberculosis infection 
in people with HIV might be reduced compared with 
performance in people without HIV.15
To our knowledge, we report the first prospective study 
of RISK11 to diagnose prevalent tuberculosis and predict 
progression to incident tuberculosis in people with HIV 
in a community setting. We aimed to establish whether 
RISK11 testing meets the minimum WHO target 
product profile for a triage test for diagnosing prevalent 
tuberculosis (90% sensitivity and 70% specificity)16 or an 
incipient tuberculosis test for predicting progression 
to active pulmonary tuberculosis (75% sensitivity 
and 75% specificity).17 Exploratory aims were to compare 
the performance of RISK11 in diagnosing pulmonary 
tuberculosis with the performance of symptom-based 
screening and the LAM assay, and to compare the 
prognostic performance of RISK11 with that of the IFN-γ 
release assay.
Methods
Study design and participants
In this prospective diagnostic and prognostic accuracy 
study, we enrolled adults with HIV from five communities 
in South Africa that were selected because of their high 
tuberculosis burden. Participants self-identified as HIV-
positive; however, confirmatory HIV testing was done at 
screening. Community-based, consecutive recruitment 
of participants without clinical suspicion of tuberculosis 
was by word-of-mouth, house-to-house visits, and liaison 
with non-governmental organisations. Recruitment did 
not specifically target household contacts, individuals 
seeking health care, or other groups at increased risk of 
tuberculosis. Eligible participants were aged 18–59 years 
(the adult age range with the highest risk of tuberculosis 
in South Africa18), and did not have known tuberculosis 
disease or household exposure to a person with multi-
drug-resistant tuberculosis within the past 3 years. 
Individuals with a history of tuberculosis within the 
previous 3 years were excluded to limit false-positive 
Xpert MTB/RIF and Xpert Ultra results due to the 
presence of dead mycobacteria or DNA. Individuals with 
comorbid risk factors for tuberculosis were excluded to 
avoid con founding test performance in people living 
with HIV. Participants were excluded if they were 
pregnant or lactating, or had any medical, surgical, or 
other condition that would interfere with the study.
This study is reported in accordance with the Standards 
for Reporting Diagnostic Accuracy Studies initiative 
guidelines.19 The study protocol was approved by the 
Institutional Human Ethics Committees of each parti-
cipating site. All participants provided written informed 
consent in their language of choice. The study protocol 
can be found in the appendix (pp 16–42). 
Masking
Participants and the study staff responsible for tuber-
culosis screening were masked to RISK11 status and 
IFN-γ release assay results, but were not masked to 
tuberculosis microbiology results. Immunology labora-
tory staff were not masked to RISK11 status or IFN-γ 
release assay results, but were masked to tuberculosis 
disease status. Before the database lock, the statistical 
analysis team were masked to RISK11 and IFN-γ release 
assay results. RISK11 and IFN-γ release assay results 
from the South African Tuberculosis Vaccine Initiative 
immunology laboratory (Cape Town, South Africa), and 
tuberculosis microbiology results from the Bio Analytical 
Research Corporation South Africa (Johannesburg, 
South Africa) were maintained in different files, which 
were not integrated until the database had been cleaned 
and locked.
Procedures
Screening procedures included taking a medical history, 
physical examination, and a HIV rapid antibody test. 
Enrolment procedures included tuberculosis screening, 
urine collection for the lateral flow Determine TB LAM Ag 
assay (Alere, Waltham, MA, USA; now owned by Abbott), 
and phlebotomy for CD4 cell count, HIV plasma viral 
load in all ART-naive participants (post-hoc also in a 
random subset of ART-treated participants), RISK11 
(using PAXgene RNA tubes [PreAnalytiX, Hombrechtikon, 
Switzerland]), and the IFN-γ release assay (QuantiFERON 
TB Gold-Plus, Qiagen, Hilden, Germany; appendix 
pp 5–6). ART-naive participants were referred for ART and 
isoniazid preventive therapy per country guidelines. 
Participants attended up to seven study visits, comprising 
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three telephone calls or field visits at months 1, 2, and 9, 
and four site visits at months 3, 6, 12, and 15 (the end of 
study visit).
Two spontaneously expectorated sputum samples, one 
for liquid mycobacterial culture (Mycobacteria Growth 
Indicator Tube [MGIT], BACTEC, Beckton Dickinson, 
Franklin Lakes, NJ, USA) and one for Xpert MTB/RIF 
(at baseline; Cepheid, Sunnyvale, CA, USA) or Xpert 
Ultra (at the end of the study; Cepheid, Sunnyvale, CA, 
USA), were collected from all participants at enrolment 
and at month 15. Sputum induction was not done 
as it is not the current standard of care in South Africa. 
Participants who were sputum-unproductive were 
assumed sputum-negative. Participants underwent 
additional tuberculosis investigation (two sputum 
samples; one for Xpert MTB/RIF and one for liquid 
mycobacterial culture) if they reported tuberculosis 
symptoms at study visits during 15 months of follow-up. 
Tuberculosis symptoms were identified by use of a 
modified WHO screen, and comprised at least one of: 
persistent unexplained cough, night sweats, fever, 
weight loss for 2 weeks or more, or any haemoptysis. If 
only one sputum result was positive, two additional 
sputum samples were collected. All participants diag-
nosed with microbiologically con firmed tuberculosis at 
baseline or during follow-up were withdrawn from the 
study and referred for curative treatment. Participants 
who were diagnosed with clinical tuberculosis or treated 
off-study, but did not meet the study endpoint definition, 
were also withdrawn.
Outcomes
The coprimary outcomes were the prevalence and 
cumulative incidence of tuberculosis disease confirmed 
by a positive Xpert MTB/RIF, Xpert Ultra, or MGIT 
culture, or a combination of such, on at least two separate 
sputum samples collected within any 30-day period. 
The secondary endpoint was tuberculosis disease micro-
biologically confirmed on at least one sputum sample. 
All Xpert Ultra trace positive results (ie, the lowest 
bacillary burden for M tuberculosis detection) were 
excluded from the analysis because of the risk of false 
positives.
Statistical analysis
We estimated the expected number of prevalent and 
incident tuberculosis cases in HIV-infected participants 
on the basis of data from previous and ongoing 
studies in South Africa. The target sample size was 
calculated by use of a stochastic model (appendix 
pp 50–51). Statistical analyses were done in RStudio, 
version 1.2.5001. Diagnostic performance for prevalent 
tuberculosis was evaluated in all participants who 
completed baseline endpoint evaluation. Evaluation 
of prognostic performance for incident tuberculosis 
excluded participants with prevalent tuberculosis at 
baseline and those who did not attend a follow-up visit. 
Participants with only one sputum sample positive for 
M tuberculosis at enrolment did not meet the primary 
two-sample endpoint and therefore were included in 
analyses of the primary incident endpoints, censored at 
their final study visit. Participants who discontinued 
follow-up before 15 months, including participants 
diagnosed with clinical tuberculosis not meeting study 
endpoint definitions, were included in the analysis as 
negative controls, but censored at their final visit or last 
negative sputum sample collection. Participants with a 
RISK11 score of 60% or higher were classified a priori 
as RISK11-positive; those with a RISK11 score less than 
60% were classified as RISK11-negative. A 60% threshold 
was selected because it balanced sensitivity and 
specificity for prediction of incident tuberculosis in case-
control studies.20 Participants without RISK11 results 
due to failed collection of the PAXgene sample and 
participants with an indeterminate RISK11 result due to 
failure of RT-PCR were excluded from the analysis.
The primary analysis evaluated relative risk (RR) for 
tuberculosis at baseline and the cumulative incidence 
ratio (CIR) during 15 months of follow-up in RISK11-
positive participants compared with RISK11-negative 
participants. Cumulative incidence (probability) was 
estimated in each group by use of a time-dependent 
non-parametric method (Nelson–Aalen estimator of 
cumulative hazard; appendix p 6). The 95% CIs and 
p values were calculated by use of a Wald-based 
approach. The 95% CIs on tuberculosis prevalence were 
calculated by use of the binomial Wilson method and the 
95% CIs on RR were calculated with a likelihood score-
based approach. p values for RR were calculated by use 
of the χ²-squared test. 
Binary receiver operating characteristic (ROC) curve 
analysis was done to calculate the diagnostic AUC. 
Diagnostic performance metrics, including sensitivity, 
specificity, positive predictive value, and negative predictive 
value, were calculated by use of standard formulas on 
the basis of binary endpoint indicators at enrolment. 
Prognostic performance metrics were calculated by use of 
non-parametric methods for time-dependent ROC curve 
analysis (appendix p 6), which allowed all participants 
(including those who discontinued early) to contribute to 
the analysis. The 95% CIs on diagnostic and prognostic 
performance estimates were calculated by use of a 
percentile bootstrap with 10 000 samples. In a post-hoc 
analysis, prognostic performance was qualitatively com-
pared between 12 months and 15 months of follow-up for 
the secondary endpoint by use of identical methods.
Post-hoc group comparisons were done by use of 
Pearson’s χ² test (for categorical data) or the Wilcoxon 
rank sum test (for continuous data) and corrected for 
multiple comparisons by use of the Benjamini–
Hochberg procedure.21 Post-hoc correlation analysis 
(Spearman’s rank correlation) of RISK11 score and HIV 
viral load was done in all participants without 
tuberculosis and with a detectable baseline viral load 
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Indicator Tube. *Any medical, 
surgical, or other condition, 
including, but not limited to, 
known diabetes (requiring oral 
or injectable therapy), liver 
disease, or alcohol misuse 
disorder, that in the opinion of 
the investigator is likely to 
interfere with RISK11 
performance; safety or efficacy 
of antiretroviral or isoniazid 
preventive therapy; or 
adherence to protocol 
requirements. †One enrolled 
participant without a PAXgene 
RNA sample and one with an 
indeterminate RISK11 result at 
baseline had primary endpoint 
prevalent tuberculosis. 
One participant with an 
indeterminate RISK11 result at 
baseline progressed to primary 
endpoint incident tuberculosis 
during follow-up. ‡Probably 
due to inadequate quality of 
the RNA sample. §Eight 
participants with one sputum 
sample-positive prevalent 
tuberculosis (three in the 
RISK11-negative group and 
five in the RISK11-positive 
group) were included in the 
primary endpoint (two or 
more positive samples) 
prognostic performance 
analysis, but excluded from 
the secondary endpoint 
(one or more positive 
samples) prognostic 
performance analysis. 
¶Participants who did not 
complete follow-up per-
protocol were included in the 
RISK11 and IGRA prognostic 
performance analysis but 
censored as non-tuberculosis 
controls at their last study visit. 
535 RISK11-negative and included in RISK11 diagnostic performance analysis 
529 without primary endpoint tuberculosis at baseline included in RISK11 primary
 endpoint prognostic performance analysis;
526 without secondary endpoint tuberculosis at baseline included in RISK11
 secondary endpoint prognostic performance  analysis§
9 withdrawn from secondary endpoint prognostic analysis
 5 with no tuberculosis excluded at day 0
 4 attended no further visits
 1 withdrew consent 
 4 with microbiologically confirmed prevalent tuberculosis 
 1 two positive samples (MGIT and Xpert)
 3 one positive sample (all MGIT)
 
7 with two positive samples withdrawn from primary endpoint
 prognostic analysis
 6 MGIT and Xpert
 1 MGIT and MGIT
6 withdrawn from primary endpoint prognostic analysis
 5 with no tuberculosis excluded at day 0
 4 attended no further visits
 1 withdrew consent 
 1 with microbiologically confirmed prevalent tuberculosis
 (two positive samples; MGIT and Xpert)
527 included in primary endpoint IGRA prognostic performance analysis;
524 included in secondary endpoint IGRA prognostic performance analysis
2 without prevalent or incident tuberculosis with missing IGRA results   
458 completed 15-month follow-up per protocol and were tuberculosis disease free 
68 did not complete 15-month per-protocol follow-up or progressed to
incident tuberculosis 
 63 did not complete per-protocol follow-up¶
 45 lost to follow-up or missed end-of-study visit
 1 clinically diagnosed tuberculosis
 3 died
 6 withdrew consent
 7 pregnant or breastfeeding
 1 withdrawal by investigator 
 5 microbiologically confirmed incident tuberculosis
 1 two positive samples (MGIT and Xpert)
 4 one positive sample 
 3 MGIT
 1 Xpert 
 
278 without primary endpoint tuberculosis at baseline included in RISK11 primary
 endpoint prognostic performance analysis;
273 without secondary endpoint tuberculosis at baseline included in RISK11
 secondary endpoint prognostic performance analysis§
12 withdrawn from secondary endpoint prognostic analysis with
 microbiologically confirmed prevalent tuberculosis 
 7 two positive samples 
 6 MGIT and Xpert
 1 MGIT and MGIT 




275 included in primary endpoint IGRA prognostic performance analysis;
270 included in secondary endpoint IGRA prognostic performance analysis
3 without prevalent or incident tuberculosis with missing IGRA results   
207 completed 15-month follow-up per protocol and were tuberculosis disease free
861 enrolled and included in symptom screening diagnostic performance analysis 
858 included in LAM assay diagnostic performance analysis 
861 had RISK11 assessment 
3 without prevalent tuberculosis at baseline and missing LAM results  
41 had no RISK11 result†
 4 without PAXgene RNA
 37 indeterminate result‡
963 participants assessed for eligibility
102 ineligible
 30 medical or surgical condition*
 21 previous tuberculosis within 3 years 
 16 pregnant or lactating 
 16 unlikely to remain in follow-up and adhere to protocol requirements
 11 HIV-negative
 8 known household multidrug-resistant tuberculosis 
 contact within the past 3 years
66 did not complete 15-month per-protocol follow-up or progressed to
incident tuberculosis 
51 did not complete per-protocol follow-up¶
 34 lost to follow-up or missed end-of-study visit
 4 clinically diagnosed tuberculosis
 6 died
 2 withdrew consent
 4 pregnant or breastfeeding
 1 protocol deviation
15 microbiologically confirmed incident tuberculosis
 7 two positive samples
 6 MGIT and Xpert
 1 Xpert and Xpert
 8 one positive sample 
 7 MGIT
 1 Xpert 
285 RISK11-positive and included in RISK11 diagnostic performance analysis 
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(>100 copies per mL). Post-hoc analysis of correlation 
between RISK11 score and the interferon-γ release assay 
was also done by use of the secondary endpoint prevalent 
and incident cases, and non-tuberculosis controls 
(Spearman’s rank correlation).
Post-hoc univariable linear regression models were built 
by use of RISK11 signature score as the depen dent variable 
among all individuals that did not develop tuberculosis to 
assess the effect of participant characteristics on RISK11 
score; collinear predictors (eg, body-mass index) were 
excluded. Sex, age, and covariables that significantly 
(p<0·05) predicted RISK11 signature score in the uni-
variable linear models were added to a multivariable linear 
regression model of RISK11 score to account for con-
founding and interaction.
Two post-hoc qualitative sensitivity analyses were done by 
use of methods identical to the primary analysis. The first 
sensitivity analysis assessed how inclusion of participants 
with sputum-negative, clinically diagnosed tuberculosis 
would have affected RISK11 prognostic performance. The 
second sensitivity analysis excluded participants that were 
receiving isoniazid preventive therapy at study enrolment 
or started isoniazid preventive therapy during study follow-
up from the diagnostic and prognostic performance 
analysis. The prespecified statistical analysis plan is detailed 










Baseline characteristics at study enrolment
Sex
Female 621 (72%) 198 (69%) 396 (74%) 0·17
Male 240 (28%) 87 (31%) 139 (26%) ··
Median age, years 35 (29–42) 33 (28–41) 35 (29–42) 0·023
Ethnicity 
Black African 724 (84%) 224 (79%) 465 (87%) 0·0019
Mixed ancestry 137 (16%) 61 (21%) 70 (13%) ··
Median body-mass index, kg/m² 24·2 (20·6–31·2) 23·0 (19·8–29·0) 25·3 (21·2–31·8) <0·0001
History of cigarette smoking‡ 334 (39%) 121 (42%) 196 (37%) 0·10
Previous tuberculosis 212 (25%) 70 (25%) 131 (24%) 0·98
Tuberculosis household contacts 160 (19%) 50 (18%) 105 (20%) 0·47
Interferon-γ release assay result 
Not available 7 (1%) 3 (1%) 2 (0%) 0·10
Negative 461 (54%) 166 (58%) 279 (52%) ··
Positive 393 (46%) 116 (41%) 254 (47%) ··
On isoniazid preventive therapy at enrolment 47 (5%) 9 (3%) 37 (7%) 0·026
Started isoniazid preventive therapy during study 370/814 (45%) 104/276 (38%) 249/498 (50%) 0·0010
Antiretroviral therapy at enrolment 
Naive 193 (22%) 107 (38%) 77 (14%) <0·0001
<6 months 115 (13%) 39 (14%) 68 (13%) ··
6–12 months 66 (8%) 23 (8%) 42 (8%) ··
>12 months 487 (57%) 116 (41%) 348 (65%) ··
Started antiretroviral therapy during study 142/193 (74%) 82/107 (77%) 56/77 (73%) 0·55
Median CD4 cell count, cells per μL 529·0 (349·5–724·5) 370·0 (234·0–562·2) 606·0 (431·0–802·8) <0·0001
Positive for tuberculosis symptoms 51 (6%) 24 (8%) 23 (4%) 0·016
Tuberculosis endpoints
Prevalent tuberculosis, n (%; 95% CI)
Primary endpoint (two or more positive samples) 10 (1·2%; 0·6–2·1) 7 (2·5%; 1·2–5·0) 1 (0·2%; 0·0–1·1) NA§
Secondary endpoint (one or more positive samples) 18 (2·1%; 1·3–3·3) 12 (4·2%; 2·4–7·2) 4 (0·7%; 0·3–1·9) NA§
Incident tuberculosis, n (rate per 100 person-years; 95% CI)
Primary endpoint (two or more positive samples) 9 (1·0; 0·3–1·6) 7 (2·5; 0·7–4·4) 1 (0·2; 0·0–0·5) NA§
Secondary endpoint (one or more positive samples) 21 (2·3; 1·3–3·2) 15 (5·2; 2·6–7·6) 5 (0·9; 0·1–1·6) NA§
Data are n (%), median (IQR), or n/N (%), unless otherwise specified. Baseline characteristics and tuberculosis endpoints by site can be found in the appendix (p 9). NA=not 
applicable. *Includes the participants with indeterminate (n=37) or missing (n=4) RISK11 scores. †p values from the Wilcoxon Rank Sum test (for continuous data) or 
Pearson’s χ² test (for categorical data). ‡Self-defined current or past cigarette smoking (ie, anyone who regarded themselves as a current or former cigarette smoker). §See 
table 2 and table 3 for RISK11 diagnostic and prognostic performance.
Table 1: Baseline characteristics of the study cohort and tuberculosis endpoints by RISK11 status
Articles
www.thelancet.com/lancetgh   Vol 9   June 2021 e847
Role of the funding source
Subject-specific experts at the Bill & Melinda Gates 
Foundation contributed to scientific discussions relating 
to protocol development and study design. The funders 
of the study had no role in data collection, data analysis, 
data interpretation, or writing of the report.
Results
Between March 22, 2017, and May 15, 2018, 963 parti-
cipants were consented and 861 were enrolled (figure 1). 
Common reasons for exclusion were comorbid conditions 
and tuberculosis disease within the previous 3 years 
(figure 1). Table 1 shows baseline characteristics of the 
study cohort. At baseline, ten of 861 enrolled participants 
were diagnosed with primary endpoint tuberculosis, 
with an overall prevalence of 1·2% (binomial Wilson 
95% CI 0·6–2·1), and 18 were diagnosed with secondary 
endpoint tuberculosis, with an overall prevalence of 2·1% 
(1·3–3·3; table 1). The prevalence of tuberculosis ranged 
from 0·0–6·7% across the five sites (appendix p 9). 
Seven (70%) of ten participants with primary endpoint 
prevalent tubercu losis and 15 (83%) of 18 participants 
with secondary end point prevalent tuberculosis reported 
no tuberculosis symptoms on screening. During a 
median follow-up of 15 months (IQR 15–15), nine 
participants progressed to primary endpoint incident 
tuberculosis, with an overall incidence of 1·0 per 
100 person-years (Nelson–Aalen 95% CI 0·3–1·6), 
and 21 participants progressed to secondary endpoint 
incident tuberculosis, with an overall incidence of 2·3 
per 100 person-years (1·3–3·2; table 1).
Of the enrolled participants, 820 (95%) had a valid 
RISK11 result, of whom 535 (65%) were RISK11-negative 
and 285 (35%) were RISK11-positive (table 1). Participants 
with indeterminate RISK11 results were excluded from 
the analysis. One enrolled participant without a PAXgene 
RNA sample available and one with an indeterminate 
RISK11 result at baseline had primary endpoint prevalent 
tuberculosis. One participant with an indeterminate 
RISK11 result at baseline progressed to primary endpoint 
incident tuberculosis during follow-up. The proportion 
of RISK11-positive participants ranged from 22% to 
45% across the five sites (appendix p 9). 665 (81%) of 
the 820 participants with RISK11 results completed 
15 months of follow-up per protocol and remained free of 
tuberculosis disease; 119 (15%) participants with RISK11 
results did not complete the study, because of withdrawal, 
death, or loss to follow-up. Early study discontinuation 
(incomplete per-protocol follow-up) was higher in the 
RISK11-positive group (51 [18%] of 278) than in the 
RISK11-negative group (63 [12%] of 529; Pearson’s χ² 
p=0·031; figure 1; appendix p 10).
There were no differences in sex, smoking his-
tory, previous tuberculosis, household contact with 
tubercu losis, or IFN-γ release assay status between 
RISK11-positive and RISK11-negative participants 
(χ² p>0·05; table 1). A significantly greater proportion of 
Figure 2: RISK11 signature score distribution
(A) RISK11 signature scores by symptom status. Box-and-whisker plots depicting RISK11 signature scores 
measured at enrolment (each dot represents a participant) in participants with symptomatic, clinical tuberculosis, 
asymptomatic, subclinical tuberculosis, or no tuberculosis. (B) RISK11 signature scores measured at enrolment by 
HIV plasma viral load (copies per mL). Prevalent and incident tuberculosis comprised all microbiologically 
confirmed secondary endpoint cases. Symptoms were recorded at the time of diagnosis for participants with 
prevalent and incident tuberculosis, and at enrolment for participants without tuberculosis. p values for 
comparison of median RISK11 signature scores between groups in box-and-whisker plots were calculated with 
the Mann-Whitney U test and corrected for multiple comparisons by use of the Benjamini-Hochberg Procedure.21 
Boxes depict the IQR, the midline represents the median, and the whiskers indicate the IQR ± (1·5 × IQR). 
The dashed line depicts the a priori RISK11 score threshold (60%). 
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RISK11-positive partici pants than RISK11-negative 
participants were of mixed ancestry (table 1). 
Median body-mass index was signifi cantly lower in 
RISK11-positive participants than in RISK11-negative 
participants, and a higher proportion of RISK11-positive 
than RISK11-negative participants reported one or 
more tuberculosis symptoms at enrolment (table 1). 
Compared with RISK11-negative participants, a higher 
proportion of RISK11-positive participants were ART-
naive and, correspondingly, had lower median CD4 cell 
counts (table 1). Fewer participants in the RISK11-
positive group than in the RISK11-negative group were 
receiving isoniazid preventive therapy at enrolment or 
commenced isoniazid preventive therapy during the 
study (table 1). History of isoniazid preventive therapy 
before study enrolment was not recorded.
Among participants without tuberculosis, the median 
RISK11 score was higher in participants with at least one 
tuberculosis symptom (median 55·5% [IQR 16·9–88·8]) 
than in those without symptoms (28·8% [13·1–72·4]; 
Wilcoxon rank-sum p=0·046; figure 2A). A similar trend 
was also observed in participants with asymptomatic 
(subclinical) and symptomatic tuberculosis; the two 
participants with symptomatic prevalent tuberculosis had 
high RISK11 scores, both greater than 90% (figure 2A). 
Among participants without tuberculosis, the median 
RISK11 score was also higher for participants with HIV 
plasma viral loads of 100 copies per mL or more 
(median 72·0% [IQR 43·5–88·7]) than for participants 
with viral loads less than 100 copies per mL (18·2% 
[10·0–38·0]; p<0·0001; figure 2B). Among 198 participants 
without tuberculosis and a HIV viral load of 100 copies 
per mL or more, there was a weak but significant 
correlation between HIV plasma viral load and 
RISK11 signature score (Spearman r=0·29; p<0·0001; 
appendix p 15).
There were eight participants with primary endpoint 
prevalent tuberculosis and RISK11 results (seven 
RISK11-positive and one RISK11-negative), with a 
prevalence of 2·5% in RISK11-positive participants and 
0·2% in RISK11-negative participants (table 1; figure 3A). 
The RR of primary endpoint prevalent tuberculosis was 
13·1 times (likelihood score-based 95% CI 2·1–81·6; 
χ² p=0·0016) higher in RISK11-positive participants 
than in RISK11-negative participants (table 2). The 
RISK11 diagnostic AUC was 88·2% (bootstrap 95% CI 
77·6–96·7) for the primary endpoint (table 2; figure 4A). 
Sensitivity was 87·5% (95% CI 58·3–100·0) and 
specificity was 65·8% (62·5–69·0; table 2) at the pre-
defined RISK11 score threshold of 60%. The diagnostic 
performance of RISK11 for the secondary endpoint 
was similar to that for the primary endpoint (table 2; 
figures 3B, 4B).
Among the 861 enrolled participants, exploratory 
analysis of tuberculosis symptom screening yielded a 
sensitivity of 30·0% (95% CI 0·0–62·5) and a specificity 
of 94·4% (92·8–95·9) for the primary tuberculosis 
endpoint (table 2). There were 14 positive LAM assays 
at baseline among 858 enrolled participants (three 
participants without tuberculosis had missing LAM 
results), with only one positive assay in a participant with 
primary endpoint pulmonary tuberculosis (table 2).
Participants with prevalent tuberculosis and who 
discontinued follow-up at the enrolment visit were 
excluded from evaluation of prognostic performance 
(figure 1); 807 participants were followed up for a 
median of 15 months and evaluated for incident 
tuberculosis. Of those with RISK11 results, eight 
people (seven RISK11-positive and one RISK11-negative) 
had primary endpoint incident tuberculosis (table 1). 
Primary endpoint tuberculosis incidence in the 
Figure 3: Prevalence and cumulative incidence of primary and secondary endpoint tuberculosis
Prevalence and cumulative incidence of primary (A) and secondary (B) endpoint tuberculosis in RISK11-positive 
and RISK11-negative participants at study enrolment and over 15 months of follow-up. Error bars and shaded 
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RISK11-positive group was 2·5 per 100 person-years 
(Nelson–Aalen 95% CI 0·7–4·4) and in the RISK-
negative group was 0·2 per 100 person-years (0·0–0·5; 
table 1). The probability of primary endpoint incident 
tuberculosis was 16·0 times (Wald-based 95% CI 
2·0–129·5; Wald-based p=0·0092) greater among 
RISK11-positive participants than among RISK11-
negative participants (table 3; figure 3A).
We next assessed RISK11 prognostic performance. 
RISK11 discriminated between primary endpoint inci-
dent tuberculosis cases and controls with an AUC of 
80·0% (bootstrap 95% CI 70·6–86·9; table 3; figure 4C). 
At the 60% threshold, sensitivity for incident tuberculosis 
was 88·6% (95% CI 43·5–98·7) and specificity was 68·9% 
(65·3–72·3; table 3). By comparison, prognostic sensi-
tivity of the IFN-γ release assay for primary endpoint 
tuberculosis was 62·1% (95% CI 25·9–88·5) and 
specificity was 56·2% (52·5–59·9; table 3). No correlation 
was observed between IFN-γ release assay response 
and RISK11 score in participants without tuberculosis 
(Spearman r=–0·07; p=0·044; appendix p 15). There was 
no difference in the risk of incident tuberculosis between 
IFN-γ release assay-positive and IFN-γ release assay-
negative participants (table 3; appendix p 15).
Prognostic performances of RISK11 and the IFN-γ release 
assay for the secondary endpoint were similar to those for 
the primary endpoint (table 3; figures 3B, 4D; appendix 
p 15). There were few incident tuberculosis cases before 
12 months, precluding analysis of prognostic performance 
for earlier time windows. Prognostic perfor mance for the 
secondary endpoint during 12 months was not different to 
performance during 15 months (appendix p 11; figure 4D). 
Five participants with negative sputum microbiology on 
study who were clinically diagnosed with tuberculosis at 
local clinics and started on empirical tuberculosis therapy 
were censored from the prognostic performance analysis at 
the time of last study visit or last negative sputum sample 
collection; censoring did not qualitatively affect RISK11 
prognostic performance (appendix p 12).
To understand factors affecting the RISK11 signature, 
we used linear regression of RISK11 scores among 
participants without prevalent tuberculosis (appendix 
p 13). After correcting for confounders and interaction 
terms, a multivariable model suggested that older age, 
male sex, a HIV plasma viral load less than 100 copies 
per mL, and higher CD4 T-cell counts were independently 
associated with lower RISK11 scores (appendix p 13). The 
higher prevalence of isoniazid preventive therapy use 
among the RISK11-negative group was predominantly 
due to the association between ART and the provision of 
isoniazid preventive therapy (data not shown), and ART 
use was associated with lower RISK11 scores (appendix 
p 13). In a sensitivity analysis, RISK11’s diagnostic 
and prognostic performance among participants who did 
not receive isoniazid preventive therapy was similar to 
performance for the whole cohort (appendix p 14).
Discussion
We evaluated the diagnostic and prognostic performance 
of RISK11 in a prospective community screening cohort. 
RISK11(60)* (n=820) Symptom screening (n=861) LAM lateral flow assay (n=858)
Not tested or inadequate sample 41† 0 3‡
Positive test 285 (35%) 51 (6%)§ 14 (2%)¶
Primary endpoint (two or more positive samples)
Risk ratio (95% CI; p value) 13·1 (2·1–81·6; p=0·0016) 6·8 (1·9–23·1; p=0·0012) 6·7 (1·1–34·5; p=0·036)
AUC 88·2% (77·6–96·7) NA NA
Sensitivity 87·5% (58·3–100·0) 30·0% (0·0–62·5) 10·0% (0·0–33·3)
Specificity 65·8% (62·5–69·0) 94·4% (92·8–95·9) 98·5% (97·6–99·3)
Positive predictive value|| 2·5% (0·7–4·4) 5·9% (0·0–13·2) 7·1% (0·0–25·0)
Negative predictive value|| 99·8% (99·4–100·0) 99·1% (98·4–99·8) 98·9% (98·2–99·5)
Secondary endpoint (one or more positive samples)
Risk ratio (95% CI; p value) 5·6 (1·9–16·4; p=0·0006) 3·2 (1·0–9·6; p=0·051) 3·5 (0·6–17·1; p=0·18)
AUC 80·3% (71·4–88·2) NA NA
Sensitivity 75·0% (50·0–94·4) 16·7% (0·0–36·4) 5·6% (0·0–18·8)
Specificity 66·0% (62·7–69·2) 94·3% (92·8–95·8) 98·5% (97·6–99·3)
Positive predictive value|| 4·2% (2·0–6·7) 5·9% (0·0–13·2) 7·1% (0·0–25·0)
Negative predictive value|| 99·3% (98·5–99·8) 98·1% (97·2–99·0) 98·0% (97·0–98·9)
Data are n (%) or % (95% CI), unless otherwise specified. AUC=area under the receiver operating characteristic curve. LAM=lipoarabinomannan. NA=not applicable. 
*A priori (60%) RISK11 score threshold. †Four participants did not have PAXgene RNA samples available and 37 had an indeterminate RISK11 result, probably because of 
inadequate quality of the RNA sample, and were excluded from the analysis. Two of these participants had prevalent primary endpoint tuberculosis and one had incident 
primary endpoint tuberculosis. ‡All three participants missing LAM assay results did not have tuberculosis at baseline. §Includes two participants with prevalent primary 
endpoint tuberculosis who were excluded from RISK11 analysis because of missing results. ¶Includes one participant with prevalent primary endpoint tuberculosis who was 
excluded from RISK11 analysis because of missing results. ||Computed by use of prevalence in the study population. 
Table 2: Performance of RISK11, symptom screening, and the LAM assay as triage or diagnostic tests for tuberculosis at baseline 
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This cohort included ART-naive and ART-treated people 
living with HIV who were not seeking health care and 
were otherwise healthy with no other important risk 
factors for tuberculosis, such as a history of tuberculosis 
or comorbidities such as diabetes. RISK11 identified 
individuals with pulmonary tuberculosis at screening, 
and predicted progression to tuberculosis in those 
without tuberculosis at screening, with performance 
approaching, but not meeting, the minimum benchmark 
in WHO’s target product profile for tuberculosis triage 
and prognostic tests.
All participants were intensively screened for tuber-
culosis at baseline and again at the end of the study with 
Xpert and mycobacterial culture on spon taneously 
expectorated sputum samples; 2·1% of participants had 
previously undiagnosed, microbio logically confirmed 
pulmonary tuberculosis at baseline. Further, more than 
70% of participants with prevalent tuberculosis were 
asymptomatic, contributing to the low sensitivity of 
tuberculosis symptom screening. This finding is 
consistent with the 36–80% prevalence of subclinical 
tuberculosis found in a review of prevalence surveys,22 
but higher than the 41% prevalence of asymptomatic 
tuberculosis reported in a prevalence survey in people 
living with HIV in South Africa.23 LAM assay testing 
was not useful for intensive case-finding in this 
community setting, with a sensitivity of 10·0%, 
consistent with previous evidence.6 However, under-
diagnosis of extrapulmonary tuberculosis due to a 
sputum-based tuberculosis endpoint might potentially 
underestimate the performance of the LAM assay. 
Additionally, the FujiLAM assay has shown markedly 
improved performance in outpatient settings compared 
with the Alere/Abbott TB LAM Ag test.24 Asymptomatic 
Figure 4: RISK11 diagnostic and prognostic performance for primary and secondary endpoint tuberculosis
Receiver operating characteristic curve depicting RISK11 diagnostic performance for the primary (A) and secondary 
(B) endpoint. The graph shows participants with symptomatic clinical prevalent tuberculosis versus symptomatic 
controls, and participants with asymptomatic subclinical prevalent tuberculosis versus asymptomatic controls. 
The shaded areas represent the 95% CIs. The solid box depicts the optimal criteria (95% sensitivity and 
80% specificity) and the dashed box depicts the minimal criteria (90% sensitivity and 70% specificity) set out in 
WHO’s target product profile for a triage test.16 Receiver operating characteristic curve depicting RISK11 prognostic 
performance for incident tuberculosis for the primary (C) and secondary (D) tuberculosis endpoints. The shaded 
areas represent the 95% CIs. The solid box depicts the optimal criteria (90% sensitivity and 90% specificity) and the 
dashed box depicts the minimal criteria (75% sensitivity and 75% specificity) set out in WHO’s target product 
profile for an incipient tuberculosis test.17 AUC=area under the receiver operating characteristic curve.
Primary endpoint 88·2% (77·6–96·7)
Asymptomatic 85·3% (73·1–95·7)
Symptomatic 98·3% (93·5−100·0)
RISK11 diagnostic AUC (95% CI)
Secondary endpoint 80·3% (71·4−88·2)
Asymptomatic 78·4% (69·1−86·8)
Symptomatic 98·3% (93·5−100·0)
RISK11 diagnostic AUC (95% CI)
Secondary endpoint (0–12 months) 
80·2% (71·3−86·8)
Secondary endpoint (0–15 months) 
74·8% (64·2−83·1)
RISK11 prognostic AUC (95% CI)
Primary endpoint (0–15 months) 
80·0% (70·6−86·9)
RISK11 prognostic AUC (95% CI)


































RISK11(60)* Interferon-γ release 
assay
Primary endpoint (two or more positive samples)
Participants included in 
analysis
807 802†
Cumulative incidence ratio 





AUC 80·0% (70·6–86·9) 70·8% (55·0–82·7)
Sensitivity 88·6% (43·5–98·7) 62·1% (25·9–88·5)
Specificity 68·9% (65·3–72·3) 56·2% (52·5–59·9)
Positive predictive value‡ 3·2% (1·5–6·6) 1·6% (0·7–3·8)
Negative predictive value‡ 99·8% (98·6–100·0) 99·2% (97·6–99·8)
Secondary endpoint (one or more positive samples)
Participants included in 
analysis
799 794†
Cumulative incidence ratio 





AUC 74·8% (64·2–83·1) 66·0% (53·8–76·4)
Sensitivity 74·9% (51·3–89·4) 64·8% (42·1–82·4)
Specificity 69·0% (65·5–72·4) 56·5% (52·7–60·2)
Positive predictive value‡ 6·5% (4·0–10·6) 4·2% (2·4–7·0)
Negative predictive value‡ 99·0% (97·5–99·6) 98·2% (96·3–99·2)
Data are % (95% CI), unless otherwise specified. Performance of RISK11 and the 
interferon-γ release assay for incident secondary endpoint tuberculosis during 
12 months of follow-up can be found in the appendix (p 11). AUC=area under the 
receiver operating characteristic curve. *A priori (60%) RISK11 score threshold. 
†Five participants without results from the interferon-γ release assay, 
all tuberculosis-negative, were excluded from the prognostic performance 
analysis. ‡Computed by use of incidence in the study population. 
Table 3: Prognostic performance of RISK11 and the interferon-γ release 
assay for incident tuberculosis over 15 months
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partici pants with tuberculosis in our study would pro-
bably have been missed by symptom screening stra-
tegies, leading to delayed presentation, increased 
morbidity, and potential transmission to close contacts.25 
This finding supports the development of better tests 
to screen for tuberculosis and find these so-called 
missing millions. However, the clinical significance of 
asymptomatic microbiologically confirmed tuberculosis 
is not clear and some of these individuals might have 
contained the disease, or even self-cured without 
treatment.26
Over the 15-month follow-up, nine participants 
(1·0 case per 100 person-years) progressed to micro-
biologically confirmed, primary endpoint incident 
pulmonary tuberculosis and 21 participants (2·3 cases 
per 100 person-years) progressed to secondary endpoint 
disease. Latent M tuberculosis infection, defined by a 
positive IFN-γ release assay or tuberculin skin test, 
includes a spectrum that spans immunological control 
and even clearance of infection through to incipient 
asymptomatic disease.27 We observed no correlation 
between IFN-γ release assay response and RISK11 score, 
which is not surprising given that the IFN-γ release 
assay measures M tuberculosis-specific T-cell responses 
and RISK11 measures a completely different immune 
response—namely, expression of IFN-stimulated genes 
predominantly in innate leukocytes.12 We found that, at 
the manufacturer-recommended threshold for latent 
infection (≥0·35 IU/mL), the IFN-γ release assay was 
not able to differentiate between people living with 
HIV who had been exposed to M tuberculosis but were 
able to control infection, from those who will progress 
to disease over 15 months, which might result in 
either unnecessary treatment or missed opportunities 
to prevent progression to disease. By contrast, the 
probability of primary endpoint incident tuberculosis 
was 16·0-times higher in RISK11-positive participants 
than in RISK11-negative participants during 15 months 
of follow-up. The 15-month prognostic window is 
encouraging given the heterogeneous nature of pro-
gression to tuberculosis disease and findings from a 
meta-analysis of transcriptomic signatures, which were 
only able to predict risk of tuberculosis disease in people 
without HIV up to 6 months before diagnosis.11 RISK11 
performed as well in people with HIV as in an intensified 
case-finding study14 of people without HIV. This result 
is surprising because HIV, and in particular high 
HIV load, is known to induce the expression of IFN-
stimulated genes and thus results in higher RISK11 
signature scores, potentially confounding the test 
result.15 However, Turner and colleagues10 found no 
difference in the diagnostic accuracy of blood transcrip-
tomic signatures by HIV status in a cohort of adults 
presenting with symptoms of tuberculosis. Higher 
median RISK11 scores in participants with HIV plasma 
viral loads of 100 copies per mL or more than in those 
with viral loads less than 100 copies per mL suggest that 
RISK11 specificity might be reduced in an exclusively 
ART-naive population, and repeat testing following 
ART initiation or alternative management pathways 
might be required. Transcriptomic signatures that are 
not considerably affected by HIV-associated induction of 
IFN-stimulated genes might perform better in this 
group.28 The finding of lower RISK11 scores in men and 
older people is in keeping with evidence that IFN-
stimulated gene expression is linked to sex29 and age.30
Current South African guidelines advocate 12 months 
of universal isoniazid preventive therapy for people living 
with HIV who have not yet received tuberculosis 
preventive therapy, irrespective of tuberculin skin testing 
or IFN-γ release assay status.31 This study suggests that 
a transcriptomic signature of tuberculosis risk, such 
as RISK11, might be more specific in determining 
need for targeted preventive therapy for people living 
with HIV. Two-thirds of the 38 million people living with 
HIV worldwide are on ART32 and, with the advent of 
well tolerated and effective short-course tuberculosis 
preventive regimens,33,34 annual or semi-annual transcrip-
tomic community-based testing of people living with 
HIV might be useful to monitor risk of progression to 
tuberculosis and target those likely to benefit from repeat 
courses of preventive therapy.
Although RISK11, which comprises 48 primer-probe 
gene expression assays, is not sufficiently parsimonious 
to be implemented as a rapid point-of-care test, this 
study offers proof of concept that a biomarker-guided, 
community-based tuberculosis screening strategy might 
be feasible for people living with HIV. A further refined, 
more concise transcriptomic signature, such as RISK6,35 
might be adapted into a point-of-care device to guide 
confirmatory investigation for tuberculosis disease and 
initiation of preventive therapy. However, it is not yet 
known whether such concise transcriptomic signatures, 
previously validated in carefully curated case-control 
studies using RNA sequencing or microarrays, will show 
similar performance in prospective, diagnostic accuracy 
studies using near-the-point-of-care or point-of-care 
technologies, such as isothermal PCR. A head-to-head 
analysis of eight concise transcriptomic signatures 
adapted to real-time PCR is also underway using RNA 
samples from this study and from people without 
HIV in the CORTIS-01 study.14 We also plan to evaluate 
the performance of proteomic and metabolomic bio-
markers, such as C-reactive protein, in these cohorts. 
Despite RISK11’s promising prognostic performance in 
this study, whether transcriptomic biomarker-targeted 
preventive therapy would be affordable and efficacious 
in preventing progression to clinical tuberculosis disease 
in people with HIV remains to be seen.
Our study has several limitations. First, reliance on 
sputum Xpert and liquid culture as the microbiological 
reference standard precludes evaluation of test per-
formance for extrapulmonary tuberculosis, which is more 
common in people with HIV than in people without HIV. 
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14 participants had positive LAM assay results, of whom 
only one was sputum M tuberculosis-positive and treated 
with anti-tuberculosis therapy; extrapulmonary disease 
cannot be ruled out in the remainder. Second, spon-
taneous spot sputum sample collection might have 
missed early or paucibacillary disease, which might have 
been detected by induced sputum, bronchoalveolar 
lavage, or by radiological imaging. Third, alternative 
diagnoses were not syste matically ascertained for 
symptomatic individuals without microbiologically con-
firmed tuberculosis. Fourth, although the regression 
analysis did not show a significant association between 
isoniazid preventive therapy and RISK11 score at 
enrolment, a greater proportion of RISK11-negative 
participants than RISK-positive participants received 
isoniazid preventive therapy during the study; therefore, 
the lower tuberculosis incidence in RISK11-negative 
participants might be in part due to isoniazid preventive 
therapy. However, we showed that RISK11’s diagnostic 
and prognostic performance among participants who 
did not receive isoniazid preventive therapy was similar 
to RISK11’s performance for the whole cohort. Fifth, 
more participants in the RISK11-positive group than 
in the RISK11-negative group discontinued the study 
early; participants in the RISK11-positive group had a 
lower median body-mass index, were more likely to be 
ART-naive and symptomatic, and had higher RISK11 
scores than participants in the RISK11-negative group. 
We can surmise that participants in the RISK11-positive 
group might have had more advanced HIV and some 
might represent missed tuberculosis cases, potentially 
resulting in an underestimation of RISK11 performance. 
Finally, although people with HIV are at high risk for 
tuberculosis and the study sites in South Africa were 
selected because of their high tuberculosis burden, 
the small number of primary endpoint tuberculosis cases 
limited the precision of diagnostic and prognostic 
estimates. However, RISK11’s diagnostic and prognostic 
performance was still significantly greater than its 
performance by chance. Case numbers were too low to 
study the effect of ART, isoniazid preventive therapy, 
CD4 cell count, HIV plasma viral load, IFN-γ release 
assay status, tuberculosis symptoms, and other clinical 
variables on RISK11 performance. Further studies are 
needed to evaluate performance in adults older than 
60 years, individuals with comorbidities, such as 
diabetes and recent tuberculosis, or household contact 
with tuberculosis, and children. We were also not able to 
study prognostic performance for time windows shorter 
than 12 months. RISK11 positive predictive values 
for primary endpoint prevalent (2·5%) and incident 
disease (3·2%) were computed with the observed 
tuberculosis prevalence (1%) and incidence rates 
(0·9% annually), which, in this ambulatory community 
setting, were lower than that typically used in esti-
mations (2%).16,17,36 Whether these results are generalisable 
to other geographical or clinical settings, such as people 
with HIV seeking health care or who are hospitalised 
with advanced HIV and low CD4 cell counts, remains to 
be seen.
Prospective field validation and implementation 
studies of rapid point-of-care real-time PCR devices that 
measure concise transcriptomic signatures are now 
needed to test the efficacy of biomarker-driven screening 
strategies to guide tuberculosis confirmatory testing and 
targeted short-course preventive therapy in HIV-affected 
communities with endemic tuberculosis.
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